Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.

European journal of cancer (Oxford, England : 1990) - 1 Jan 2016

Lambrechts Sandrina, Smeets Dominiek, Moisse Matthieu, Braicu Elena Ioana, Vanderstichele Adriaan, Zhao Hui, Van Nieuwenhuysen Els, Berns Els, Sehouli Jalid, Zeillinger Robert, Darb-Esfahani Silvia, Cacsire Castillo-Tong Dan, Lambrechts Diether, Vergote Ignace

Abstract excerpt

BACKGROUND: Most high-grade serous ovarian carcinoma (HGSOC) patients benefit from first-line platinum-based chemotherapy, but progressively develop resistance during subsequent lines. Re-activating BRCA1 or MDR1 mutations can underlie platinum resistance in end-stage patients. However, little is known about resistance mechanisms occurring after a single line of platinum, when patients still qualify for other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ovarian Epithelial
Share to Fanconi Anemia Complementation Group A Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Genetic Heterogeneity

Share to Neoplasm Recurrence, Local

Share to Neoplasms, Glandular and Epithelial

Share to Platinum Compounds

Source

Identifiers

PMID: 26693899
DOI: 10.1016/j.ejca.2015.11.001

Genes

BRCA1
CCNE1
ERBB2
MECOM

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.PMID 26693899Read ↗

Platinum resistance induces diverse evolutionary trajectories in high grade serous ovarian cancerSemantic proximity Read ↗

The genomic landscape of recurrent ovarian high grade serous carcinoma: the BriTROC-1 studySemantic proximity Read ↗

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancerSemantic proximity Read ↗

Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.Semantic proximity Read ↗

High-Grade Serous Ovarian Carcinoma in the Genomics Era: Current Applications, Challenges and Future Directions.Semantic proximity Read ↗

Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivorsSemantic proximity Read ↗

Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”Semantic proximity Read ↗

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination SystemSemantic proximity Read ↗

The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer.Semantic proximity Read ↗

Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 MutationsSemantic proximity Read ↗

Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian CancerSemantic proximity Read ↗

The mutation and clonality profile of genomically unstable high grade serous ovarian cancer is established early in tumor development and conserved throughout therapy resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.